AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25982133 — intervention group
Group type: COMPARATOR
Intervention: Subanaesthetic ketamine (0.29 mg kg(‐1) h(‐1) for 1 h, followed by 0.57 mg kg(‐1) h(‐1) for another hour)
Number of subjects: 12
Study 25982133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23813743 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg 4-aminopyridine (4-AP) four times a day for 3 days
Number of subjects: 27
Study 23813743 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg 4-aminopyridine (4-AP) four times a day for 4 days
Number of subjects: 27
Study 23813743 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP)
Number of subjects: 27
Study 23813743 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 21541781 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 600 mg
Number of subjects: 56
Study 21541781 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 300 mg
Number of subjects: 56
Study 21541781 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan
Number of subjects: 56
Study 21541781 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-132577
Number of subjects: 56
Study 21541781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 18696107 — intervention group
Group type: EXPERIMENTAL
Intervention: High similarity between targets and distractors
Number of subjects: 0
Study 18696107 — intervention group
Group type: EXPERIMENTAL
Intervention: Targets following one another directly (lag-1 condition)
Number of subjects: 0
Study 18696107 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-committing resources to target processing
Number of subjects: 0
Study 17400413 — intervention group
Group type: EXPERIMENTAL
Intervention: computer-based hormone therapy decision-aid
Number of subjects: 177
Study 17400413 — intervention group
Group type: COMPARATOR
Intervention: printed pamphlet (control)
Number of subjects: 177
Study 15121737 — intervention group
Group type: EXPERIMENTAL
Intervention: CT measurements at L4‐L5
Number of subjects: 200
Study 15121737 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measurements at L4‐L5
Number of subjects: 200
Study 15121737 — intervention group
Group type: EXPERIMENTAL
Intervention: CT measurements
Number of subjects: 200
Study 15121737 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measurements
Number of subjects: 200
Study 15121737 — intervention group
Group type: EXPERIMENTAL
Intervention: CT and MRI measurements
Number of subjects: 200
Study 11590704 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-type diet
Number of subjects: 42
Study 11590704 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 42
Study 10419902 — intervention group
Group type: EXPERIMENTAL
Intervention: MDR1/P-glycoprotein expression
Number of subjects: 352
Study 10419902 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional drug efflux (assessed using Di(OC)(2) and Rhodamine 123)
Number of subjects: 352
Study 10419902 — intervention group
Group type: EXPERIMENTAL
Intervention: MRP1 expression
Number of subjects: 352
Study 10419902 — intervention group
Group type: EXPERIMENTAL
Intervention: LRP expression
Number of subjects: 352
Study 10419902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopsorine-resistant efflux
Number of subjects: 352
Study 7587453 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training consisting of 1 h of group walking twice daily, with intensity stratified into four levels based on initial exercise capacity.
Number of subjects: 42
Study 7587453 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 42
Study 2276014 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative combination chemotherapy (5‐fluorouracil, lomustine (CCNU) and vincristine)
Number of subjects: 334
Study 2276014 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy (Control)
Number of subjects: 334
Study 2276014 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative combination chemotherapy
Number of subjects: 334
Study 6157615 — intervention group
Group type: EXPERIMENTAL
Intervention: CVPP scheme (modified MOPP scheme)
Number of subjects: 72
Study 6157615 — intervention group
Group type: COMPARATOR
Intervention: Synchronization therapy (control group)
Number of subjects: 72
Study 6157615 — intervention group
Group type: EXPERIMENTAL
Intervention: CVPP scheme (for advanced non-Hodgkin lymphomas)
Number of subjects: 72
Study 6157615 — intervention group
Group type: COMPARATOR
Intervention: Synchronization therapy (for advanced non-Hodgkin lymphomas)
Number of subjects: 72
Study 31641913 — intervention group
Group type: EXPERIMENTAL
Intervention: QL2 regional anesthesia with 150 mg of ropivacaine combined with standard analgesia
Number of subjects: 62
Study 31641913 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention with standard analgesia
Number of subjects: 62
Study 31469923 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable poly-L-lactic acid (PLLA)
Number of subjects: 0
Study 31469923 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable poly-D,L-lactic acid (PDLLA)
Number of subjects: 0
Study 31469923 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 0
Study 27403887 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA® cream (anaesthetic cream), n = 34, applied on the volar part of the forearm, treatment repeated at increasing intervals over 8 weeks.
Number of subjects: 70
Study 27403887 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream, n = 36, applied on the volar part of the forearm, treatment repeated at increasing intervals over 8 weeks.
Number of subjects: 70
Study 25271011 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 3 (250,000 IU, single dose in November)
Number of subjects: 28
Study 25271011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23672272 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive school-based intervention including motivational counseling, Internet-based feedback, and after-school physical activity club
Number of subjects: 1200
Study 23672272 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving the intervention)
Number of subjects: 1200
Study 21177840 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher indoor NO(2) levels (per logged unit increase)
Number of subjects: 409
Study 19013548 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete anterior cutout seat
Number of subjects: 30
Study 19013548 — intervention group
Group type: COMPARATOR
Intervention: Standard seat
Number of subjects: 30
Study 19013548 — intervention group
Group type: COMPARATOR
Intervention: Partial cutout seat
Number of subjects: 30
Study 17202008 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (2 mL, 40 mg, 2%)
Number of subjects: 180
Study 17202008 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (2 mL, 20 mg)
Number of subjects: 180
Study 17202008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 mL normal saline)
Number of subjects: 180
Study 12972673 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (60%)
Number of subjects: 8
Study 12972673 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (55%)
Number of subjects: 8
Study 12972673 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss regimen
Number of subjects: 8
Study 10973445 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV type 1 (HIV-1) immunogen (Remune)
Number of subjects: 297
Study 10973445 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant control
Number of subjects: 297
Study 8793044 — intervention group
Group type: EXPERIMENTAL
Intervention: High chemical odor intolerance group (n = 15)
Number of subjects: 15
Study 8793044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy-containing diet
Number of subjects: 15
Study 8793044 — intervention group
Group type: COMPARATOR
Intervention: Low chemical odor intolerance group (n = 15)
Number of subjects: 15
Study 1480917 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg nightly (increased to 40 mg if cholesterol > 200 mg/dl after 6 weeks)
Number of subjects: 31
Study 1480917 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg twice daily (dose kept constant)
Number of subjects: 31
Study 6500445 — intervention group
Group type: EXPERIMENTAL
Intervention: Split tetanus vaccine
Number of subjects: 200
Study 6500445 — intervention group
Group type: COMPARATOR
Intervention: Normal adsorbed toxoid vaccine
Number of subjects: 200
Study 6500445 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 2944434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin by continuous infusion
Number of subjects: 19
Study 2944434 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal infusion rate)
Number of subjects: 19
Study 29741630 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning algorithms based on parent-reported questionnaires and home videos
Number of subjects: 162
Study 27020698 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel of chamomile
Number of subjects: 48
Study 27020698 — intervention group
Group type: COMPARATOR
Intervention: Cream of urea
Number of subjects: 48
Study 23978956 — intervention group
Group type: COMPARATOR
Intervention: manikin+teacher instruction (control group)
Number of subjects: 593
Study 23978956 — intervention group
Group type: EXPERIMENTAL
Intervention: manikin+video instruction
Number of subjects: 593
Study 23978956 — intervention group
Group type: EXPERIMENTAL
Intervention: foam dice+plastic bag+peer training+teacher instruction
Number of subjects: 593
Study 23978956 — intervention group
Group type: EXPERIMENTAL
Intervention: foam dice+plastic bag+peer training+video instruction
Number of subjects: 593
Study 23201763 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (4 weeks loading phase of 4.8 g/day and 3.2 g/day thereafter)
Number of subjects: 41
Study 23201763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 20522841 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 microg and 600 microg
Number of subjects: 1732
Study 20522841 — intervention group
Group type: COMPARATOR
Intervention: Formoterol 12 microg
Number of subjects: 1732
Study 20522841 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol (both doses)
Number of subjects: 1732
Study 20522841 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol
Number of subjects: 1732
Study 20522841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1732
Study 18272750 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 51
Study 18272750 — intervention group
Group type: COMPARATOR
Intervention: Simulated therapeutic touch
Number of subjects: 51
Study 18272750 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 51
Study 15998756 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein intake; specific dosage and duration not mentioned.
Number of subjects: 0
Study 15998756 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle interventions (controlling body weight, reducing dietary salt, increasing physical activity, maintaining moderate alcohol use); specific details not mentioned.
Number of subjects: 0
Study 12757058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (50 mg initially, increased to 100 mg or decreased to 25 mg depending on efficacy and/or tolerability)
Number of subjects: 125
Study 12757058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 12757058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 125
Study 10861311 — intervention group
Group type: EXPERIMENTAL
Intervention: Diurnal cortisol slope
Number of subjects: 104
Study 10861311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol rhythm
Number of subjects: 104
Study 10861311 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cell count and activity
Number of subjects: 104
Study 8981290 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized peak power output (PPopt)
Number of subjects: 37
Study 8981290 — intervention group
Group type: COMPARATOR
Intervention: Corrected peak power output (PPcorr)
Number of subjects: 37
Study 8981290 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized pedalling rate (RPMopt)
Number of subjects: 37
Study 8981290 — intervention group
Group type: COMPARATOR
Intervention: Corrected pedalling rate (RPMcorr)
Number of subjects: 37
Study 1478168 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg twice daily for one year)
Number of subjects: 98
Study 6478732 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 21
Study 6478732 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 21
Study 30497962 — intervention group
Group type: EXPERIMENTAL
Intervention: OC-Sensor (Eiken Chemical, Tokyo, Japan)
Number of subjects: 21078
Study 30497962 — intervention group
Group type: EXPERIMENTAL
Intervention: FOB-Gold (Sentinel Diagnostics, Milan, Italy)
Number of subjects: 21078
Study 30497962 — intervention group
Group type: COMPARATOR
Intervention: Both FIT assays
Number of subjects: 21078
Study 29262308 — intervention group
Group type: COMPARATOR
Intervention: Multiple‐Modality (M2) exercise
Number of subjects: 127
Study 29262308 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple‐Modality (M4) training
Number of subjects: 127
Study 27179288 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based coached depression self-care intervention
Number of subjects: 215
Study 27179288 — intervention group
Group type: COMPARATOR
Intervention: Noncoached intervention
Number of subjects: 215
Study 24768247 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-reduction-by-half group
Number of subjects: 61
Study 24768247 — intervention group
Group type: COMPARATOR
Intervention: Dose maintenance group
Number of subjects: 61
Study 22892151 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 34
Study 22892151 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 34
Study 20819899 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (0.5 mg/kg per day)
Number of subjects: 0
Study 20819899 — intervention group
Group type: EXPERIMENTAL
Intervention: Other glucocorticoid doses and preparations
Number of subjects: 0
Study 19116707 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (types 6, 11, 16, 18)
Number of subjects: 123
Study 15829777 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring approach (SMA)
Number of subjects: 45
Study 15829777 — intervention group
Group type: COMPARATOR
Intervention: Control group (CR only)
Number of subjects: 45
Study 12892188 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL retained
Number of subjects: 211
Study 12892188 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL excised
Number of subjects: 211
Study 12892188 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL substituted with a posterior stabilised insert
Number of subjects: 211
Study 12892188 — intervention group
Group type: COMPARATOR
Intervention: PCL released
Number of subjects: 211
Study 11081531 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg prednisolone daily for 2 weeks
Number of subjects: 67
Study 11081531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 9002329 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent rhesus‐human reassortant rotavirus vaccine (4 x 10(4) plaque‐forming units/dose)
Number of subjects: 540
Study 9002329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 540
Study 1623865 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 154
Study 1623865 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 154
Study 3883593 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (RATG)
Number of subjects: 50
Study 3883593 — intervention group
Group type: COMPARATOR
Intervention: High oral doses of prednisone
Number of subjects: 50
Study 30768394 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM)
Number of subjects: 118
Study 30768394 — intervention group
Group type: COMPARATOR
Intervention: Community interventions (Control)
Number of subjects: 118
Study 27977327 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative right potentiation
Number of subjects: 0
Study 27977327 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative left potentiation
Number of subjects: 0
Study 27977327 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 0
Study 27563602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermaxillary fixation with IMF screws (Group B)
Number of subjects: 60
Study 27563602 — intervention group
Group type: COMPARATOR
Intervention: Erich arch bars (Group A)
Number of subjects: 60
Study 24949989 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-elastic heat-activated arch wires
Number of subjects: 82
Study 24949989 — intervention group
Group type: COMPARATOR
Intervention: Conventional multi-stranded stainless steel arch wires
Number of subjects: 82
Study 22337714 — intervention group
Group type: EXPERIMENTAL
Intervention: FCR (fludarabine and cyclophosphamide in combination with rituximab)
Number of subjects: 165
Study 22337714 — intervention group
Group type: COMPARATOR
Intervention: FCCam (fludarabine and cyclophosphamide in combination with alemtuzumab)
Number of subjects: 165
Study 22337714 — intervention group
Group type: EXPERIMENTAL
Intervention: FCR
Number of subjects: 165
Study 22337714 — intervention group
Group type: COMPARATOR
Intervention: FCCam
Number of subjects: 165
Study 20363548 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 40
Study 20363548 — intervention group
Group type: COMPARATOR
Intervention: Closed treatment
Number of subjects: 40
Study 20363548 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 18503008 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized oral mixed meal
Number of subjects: 18
Study 18503008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal glucose infusion
Number of subjects: 18
Study 18503008 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (comparison group)
Number of subjects: 18
Study 18503008 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma levels of PYY(1‐36)
Number of subjects: 18
Study 18503008 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma levels of PYY(3‐36)
Number of subjects: 18
Study 15816811 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment at a dosage of 1.6 IU/day (0.53 mg/day) for 6 months followed by 12 months of active GH treatment
Number of subjects: 19
Study 15816811 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 19
Study 15816811 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment follow-up after cessation of GH treatment
Number of subjects: 19
Study 12442928 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (0.375 microg kg(‐1) min(‐1))
Number of subjects: 30
Study 12442928 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (0.2 microg kg(‐1) min(‐1))
Number of subjects: 30
Study 12442928 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 30
Study 10368055 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I bovine collagen barrier membrane
Number of subjects: 19
Study 10368055 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA/PLA copolymer barrier membrane
Number of subjects: 19
Study 8525418 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA
Number of subjects: 1095
Study 8525418 — intervention group
Group type: COMPARATOR
Intervention: Thick Blood Film (TBF)
Number of subjects: 1095
Study 8525418 — intervention group
Group type: COMPARATOR
Intervention: Quantitative Buffy Coat (QBC)
Number of subjects: 1095
Study 2321293 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental room
Number of subjects: 292
Study 2321293 — intervention group
Group type: COMPARATOR
Intervention: Traditional delivery room
Number of subjects: 292
Study 227618 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month exercise program (3-4 weekly sessions)
Number of subjects: 100
Study 227618 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained previous exercise habits)
Number of subjects: 100
Study 31688649 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation of the knee extensors
Number of subjects: 13
Study 31688649 — intervention group
Group type: COMPARATOR
Intervention: Control leg (no stimulation)
Number of subjects: 13
Study 31688649 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Number of subjects: 13
Study 30859637 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk training (12-week exercise program with trunk strengthening/motor control exercises)
Number of subjects: 64
Study 30859637 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk training
Number of subjects: 64
Study 30859637 — intervention group
Group type: COMPARATOR
Intervention: Walking-balance training (control group)
Number of subjects: 64
Study 27521821 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol (50 mg orally, 3 times daily)
Number of subjects: 30
Study 27521821 — intervention group
Group type: COMPARATOR
Intervention: Diosmin/Hesperidin (450/50 mg orally, twice daily)
Number of subjects: 30
Study 26227554 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious Group
Number of subjects: 212
Study 26227554 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 212
Study 23296063 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/platinum chemotherapy followed by liposomal doxorubicin and gemcitabine (Group B)
Number of subjects: 113
Study 23296063 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/platinum chemotherapy followed by platinum compounds, docetaxel and oral etoposide (Group A)
Number of subjects: 113
Study 23296063 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-relapse treatment in Group B
Number of subjects: 113
Study 23296063 — intervention group
Group type: COMPARATOR
Intervention: Post-relapse treatment in Group A
Number of subjects: 113